Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes.
Historical and current end-of-day data provided by FACTSET. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
See JSI’s FINRA BrokerCheck and Form CRS for further information. When you enable T-Bill investing on the Public platform, you open a separate brokerage account with JSI (the “Treasury Account“). LOS ANGELES—-Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Accelerate Diagno… Accelerate Diagnostics has 99,099,480 shares outstanding.
Accelerate Diagnostics stock has received a consensus rating of hold. The average rating score is and is based on 0 buy ratings, 1 hold ratings, and 0 sell ratings. What was the 52-week low for Accelerate Diagnostics stock? The low in the last 52 weeks of Accelerate Diagnostics stock was 0.46. According to the current price, Accelerate Diagnostics is 105.47% away from the 52-week low. What was the 52-week high for Accelerate Diagnostics stock?
JSI and Jiko Bank are not affiliated with Public Holdings, Inc. (“Public”) or any of its subsidiaries. None of these entities provide legal, tax, or accounting advice. You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy. JSI uses funds from your Treasury Account to purchase T-bills in increments of $100 “par value” (the T-bill’s value at maturity).
The average Accelerate Diagnostics stock price for the last 52 weeks is 1.10. All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns. U.S. Treasuries (“T-Bill“) investing services on the Public Platform are offered by Jiko Securities, Inc. (“JSI”), a registered broker-dealer and member of FINRA & SIPC.
- If you have any questions about our features, please contact us at Information provided by Stash Support is for informational and general educational purposes only and is not investment or financial advice.
- For US and Canadian Stocks, the Overview page includes key statistics on the stock’s fundamentals, with a link to see more.
- 2 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Accelerate Diagnostics in the last twelve months.
Shares Sold ShortThe total number of shares of a security that have been sold short and not yet repurchased.Change from LastPercentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.Percent of FloatTotal short positions relative to the number of shares available to trade. If you purchase this plan, you will receive Financial Counseling Advice which is impersonal investment advice. ‡ Group life insurance coverage provided through Avibra, Inc.
Short position overnight fee
Early access to direct deposit funds depends on when the payor sends the payment file. We generally make these funds available on the day the payment file is received, which may be up to 2 days earlier than the scheduled payment date. The date shareholders were paid out for the last dividend issued. Of Accelerate Diagnostics Inc stock, you’ll need to sign up for Stash and open a personal portfolio. Needs to review the security of your connection before proceeding. Information is provided ‘as-is’ and solely for informational purposes and is not advice.
The P/E ratio of Accelerate Diagnostics is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. In the past three months, Accelerate Diagnostics insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $142,098.00 in company stock.
PROCEPT BioRobotics Corporation delivered earnings and revenue surprises of -5.66% and 0.33%, respectively, for the quarter ended December 2022. Realtime https://day-trading.info/ quote and/or trades are not sourced from all markets. Provide specific products and services to you, such as portfolio management or data aggregation.
Rapid Micro Biosystems, Inc. (RPID) Reports Q3 Loss, Tops Revenue Estimates
Real-time quotes, advanced visualizations, backtesting, and much more. The value of shares and ETFs bought through a share dealing account can fall as well as rise, which could mean getting back less than you originally put in. To be able to trade stocks like this, create an account and apply for a stock listing. The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023. Accelerate Diagnostics’ stock was trading at $0.7060 on January 1st, 2023. Since then, AXDX stock has decreased by 32.0% and is now trading at $0.48.
The value of T-bills fluctuate and investors may receive more or less than their original investments if sold prior to maturity. T-bills are subject to price change and availability – yield is subject to change. Past performance is not indicative of future performance. Investments in T-bills involve a variety of risks, including credit risk, interest rate risk, and liquidity risk.
Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed what is day trading and how does it work quotes. Each plan can help you reach different goals and offers a unique combination of financial accounts and features.
View analysts price targets for AXDX or view top-rated stocks among Wall Street analysts. 2 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Accelerate Diagnostics in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock.
Only individuals ages and who are residents of one of the 50 U.S. states or DC are eligible for group life insurance coverage, subject to availability. Individuals with certain pre-existing medical conditions may not be eligible for the full coverage above, but may instead receive less coverage. All insurance products are subject to state availability, issue limitations and contractual terms and conditions, any of which may change at any time and without notice. Stash may receive compensation from business partners in connection with certain promotions in which Stash refers clients to such partners for the purchase of non-investment consumer products or services.
Total Annual Return %
We’d like to share more about how we work and what drives our day-to-day business. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. AXDX has a forward dividend yield of 0.64%.SeeAXDX’s full dividends and stock split historyon the Dividend tab.
You can buy or sell AXDX and other ETFs, options, and stocks. Accelerate Diagnostics released its earnings results on Nov 14, 2022. The company reported -$0.167 earnings per share for the quarter, beating the consensus estimate of -$0.195 by $0.028.
If you have any questions about our features, please contact us at Information provided by Stash Support is for informational and general educational purposes only and is not investment or financial advice. You may subsequently choose to open one or more investment advisory account. To begin investing on Stash, you must be approved from an account verification perspective and open a brokerage account. To be eligible to receive a Stock Reward through stock party, you must complete the account registration process and open an individual taxable brokerage account (“Personal Portfolio”) that is in good standing. Stash through the “Diversification Analysis” feature does not rebalance portfolios or otherwise manage the Personal Portfolio Account for clients on a discretionary basis.
An indication of interest to purchase securities involves no obligation or commitment of any kind. According to 8 analysts, the average rating for AXDX stock is “Buy.” The 12-month stock price forecast is $2.04, which is an increase of 325.00% from the latest price. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed.
See AXDX stock price and Buy/Sell Accelerate Diagnostics. Discuss news and analysts’ price predictions with the investor community. Los Angeles, California–(Newsfile Corp. – October 26, 2022) – The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of A… Los Angeles, California–(Newsfile Corp. – October 27, 2022) – The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of A… Sign up for a Robinhood brokerage account to buy or sell AXDX stock and options commission-free. Robinhood gives you the tools you need to put your money in motion.